Skip to main content

Biologics May be Effective for Erythrodermic Psoriasis

Some biologics, such as ustekinumab (Stelara) and infliximab (Remicade), were found to be safe and effective for patients with erythrodermic psoriasis in a recent study published in the Journal of the American Academy of Dermatology.

In the systemic review, the researchers analyzed treatment response and tolerability of biologic medications in 43 studies with a total of 179 patients with erythrodermic psoriasis. Baseline Psoriasis Area Severity Index (PASI) score, PASI improvement score, and adverse events were reported, and adequate treatment was defined as PASI ≥ 50.
__________________________________________________________
Related content

Tailoring Treatments for Psoriasis
Neck and Head Psoriasis Treated With Biologic
__________________________________________________________

Most patients responded at some point during treatment, the researchers said. They found a higher level of evidence supported the effectiveness of infliximab, ustekinumab, ixekizumab (Taltz), and guselkumab (Tremfya).

The most commonly reported adverse event was infection (n=35), the researchers said.

“Patients with erythrodermic psoriasis treated with biologics demonstrated positive responses and treatment was well-tolerated with a weak recommendation and limited quality of evidence in favor of infliximab, ustekinumab, ixekizumab, and guselkumab,” they concluded.

Reference

Carrasquillo OY, Pabón-Cartagena G, Falto-Aizpurua LA, et al. Treatment of erythrodermic psoriasis with biologics: A systematic review [published online April 2, 2020]. J Am Acad Dermatol. doi:10.1016/j.jaad.2020.03.073

 

Back to Top